These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
441 related items for PubMed ID: 15824127
1. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. Hörl WH, Vanrenterghem Y, Canaud B, Mann J, Teatini U, Wanner C, Wikström B. Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127 [Abstract] [Full Text] [Related]
2. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Jacobs C, Frei D, Perkins AC. Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128 [Abstract] [Full Text] [Related]
3. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group. Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642 [Abstract] [Full Text] [Related]
4. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy. Voravud N, Sriuranpong V. J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676 [Abstract] [Full Text] [Related]
5. Individualizing anaemia treatment: a discussion of case histories. Muirhead N. Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi37-43. PubMed ID: 15958826 [Abstract] [Full Text] [Related]
6. [Spanish survey on anaemia management]. Pérez García R. Nefrologia; 2003 Jun; 23(4):300-11. PubMed ID: 14558329 [Abstract] [Full Text] [Related]
7. Anemia management and treatment response in patients on hemodialysis: the MAR study. Portolés J, López-Gómez JM, Aljama P. J Nephrol; 2006 Jun; 19(3):352-60. PubMed ID: 16874697 [Abstract] [Full Text] [Related]
8. Dose tailoring strategies in haemodialysis patients: a discussion of case histories. Kleophas W. Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi31-6. PubMed ID: 15958825 [Abstract] [Full Text] [Related]
9. ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data. Locatelli F, Covic A, Macdougall IC, Wiecek A, ORAMA Study Group. J Nephrol; 2008 Jun; 21(4):592-603. PubMed ID: 18651551 [Abstract] [Full Text] [Related]
10. What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease. Fishbane S. Blood Purif; 2007 Jun; 25(1):53-7. PubMed ID: 17170538 [Abstract] [Full Text] [Related]
11. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study. Heras P, Kritikos K, Hatzopoulos A, Mitsibounas D. Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619 [Abstract] [Full Text] [Related]
12. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort. Yong K, Kairaitis L. Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296 [Abstract] [Full Text] [Related]
13. Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis. Wong CF, McCarthy M, Howse ML, Williams PS. Ren Fail; 2007 Apr; 29(6):653-9. PubMed ID: 17763158 [Abstract] [Full Text] [Related]
14. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM. Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210 [Abstract] [Full Text] [Related]
15. Once weekly treatment with epoetin-beta. Locatelli F. Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi26-30. PubMed ID: 15958823 [Abstract] [Full Text] [Related]
16. Renal anemia: comparing current Eastern and Western European management practice (ORAMA). Wiecek A, Covic A, Locatelli F, Macdougall IC, ORAMA study group. Ren Fail; 2008 Jun; 30(3):267-76. PubMed ID: 18350446 [Abstract] [Full Text] [Related]
17. [Iron deficiency is a common cause of bad response to epoetin treatment. It's important to follow iron status--not only the Hb value]. Wallerstedt SM, Ljungman S, Broms E, Andrén L. Lakartidningen; 2008 Jun; 102(37):2550-1, 2553-5. PubMed ID: 16200900 [Abstract] [Full Text] [Related]
18. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Bárány P, Müller HJ. Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv10-iv18. PubMed ID: 17526545 [Abstract] [Full Text] [Related]
19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators. Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286 [Abstract] [Full Text] [Related]
20. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed? Berns JS. Semin Dial; 2005 Apr; 18(1):22-9. PubMed ID: 15663760 [Abstract] [Full Text] [Related] Page: [Next] [New Search]